28 results on '"Brown, Bob D."'
Search Results
2. First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection
3. Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria
4. Data from Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
5. Supplementary legends from β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models
6. Data from β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models
7. Figure S1, Figure S2, Figure S3 from β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models
8. supplemental figure legends from Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
9. Supplemental figures S1-9 from Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
10. Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1
11. Hepatic Lactate Dehydrogenase A : An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria
12. Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria
13. Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria.
14. Abstract 1502: KRAS RNAi therapy in preclinical models of pancreatic cancer sensitizes tumors to checkpoint blockade by affecting the tumor microenvironment
15. RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade
16. Abstract B03: RNAi-mediated β-catenin inhibition sensitizes noninflamed tumors to immune checkpoint blockade
17. Direct Inhibition of β-catenin: A new strategy for colorectal cancer
18. Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria
19. Inhibition of Glycogen Synthase II with RNAi Prevents Liver Injury in Mouse Models of Glycogen Storage Diseases
20. Abstract 2759: Rational combinations for immune checkpoint blockade using β-catenin RNAi therapy
21. Effect of RNAi-based β-catenin inhibition on immunosuppressive Wnt-activated tumors in combination with IDOi/PD-1 immunotherapy.
22. β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models
23. Abstract 1229: RNAi-based β-catenin inhibition in combination with MEK inhibition promotes synergistic anti-tumor efficacy and overcomes resistance with MEK inhibition promotes synergistic anti-tumor efficacy and overcomes resistance
24. RNAi-mediated beta-catenin inhibition to promote T-cell infiltration and antitumor activity in combination with immune checkpoint blockade.
25. RNAi mediated silencing of STAT3/PD-L1in tumor-associated immune cells induces robust anti-tumor effects in immunotherapy resistant tumors
26. Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
27. Abstract B20: EnCore-LNP mediated tumor delivery of MYC and CTNNB1 Dicer Substrate RNAs (DsiRNAs)
28. Direct Inhibition of β-catenin: A new strategy for colorectal cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.